Investments in vaccine manufacturing across Asia Pacific are driving demand for biopharmaceutical process analytical technology (PAT), as governments and pharmaceutical companies expand production capacity and strengthen pandemic preparedness. The global biopharmaceutical process analytical technology market is expected to grow from $1.96 billion in 2026 to $4.32 billion by 2031, at a compound annual growth rate (CAGR) of 17.1%, according to the report.
Asia Pacific is expected to hold the largest share of the market during the forecast period, supported by expanding immunisation programmes and investments in advanced manufacturing facilities across China, India, Japan, South Korea, and Australia.
Market Growth Drivers
The report said increasing production of conventional and next-generation vaccines, including mRNA, recombinant protein, and viral vector vaccines, is driving demand for technologies that enable real-time process monitoring, process optimisation, and quality assurance.
The expansion of contract development and manufacturing organisations (CDMOs), alongside the adoption of continuous bioprocessing, single-use technologies, and automated manufacturing systems, is also accelerating the use of analytical tools such as spectroscopy, chromatography, and mass spectrometry.
Industry Trends
Companies are increasingly adopting real-time monitoring and predictive analytics to improve production, reduce batch failures, and shorten development timelines. By product type, the liquid chromatography/high-performance liquid chromatography (HPLC) segment is projected to record the fastest growth, with a CAGR of 17.7% between 2026 and 2031.
Related: Most unpaid carers struggle with wellbeing
By technology, analysers accounted for the largest market share at 38% in 2025. Online systems held the largest share by system type at 45%, whilst biosimilars and biologics represented the largest application segment with a 39.9% share.
As the demand for biopharmaceutical process analytical technology continues to grow, it’s likely that manufacturers will need to adapt to new technologies and processes to remain competitive. This could involve investing in new equipment and training staff to use it effectively.
Regional Outlook
MarketsandMarkets said growing alignment with international quality standards and the focus on producing export-quality vaccines are expected to further support adoption of process analytical technologies across the region, helping manufacturers improve efficiency, ensure batch consistency, and reduce production risks.
The report highlights the importance of regulatory compliance in the biopharmaceutical industry, as companies must adhere to strict guidelines to ensure the quality and safety of their products.
In terms of market share, Asia Pacific is expected to dominate the global biopharmaceutical process analytical technology market during the forecast period, driven by the expanding immunisation programmes and investments in advanced manufacturing facilities across the region.